Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Anup K. Majumdar"'
Autor:
Erik T. te Beek, Jacqueline B. McCrea, Joop M. A. van Gerven, Kristien Van Dyck, Kevin J. Petty, Anup K. Majumdar, Cynthia Gargano, Erica S. Klaassen, Gail Murphy, Diana Selverian, Daniel Tatosian
Publikováno v:
The Journal of Clinical Pharmacology. 53:846-856
Recent interest in NK1 receptor antagonists has focused on a potential role in the treatment of drug addiction and substance abuse. In the present study, the potential for interactions between the NK1 receptor antagonist aprepitant and alcohol, given
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2a26d6a627472d39af31023eabfdcb7d
https://doi.org/10.1002/jcph.120
https://doi.org/10.1002/jcph.120
Autor:
M. Gail Murphy, Howard E. Greenberg, Anup K. Majumdar, Walter K. Kraft, Matthew P. Braun, Dennis C. Dean, Keith Gottesdiener, Kevin J. Petty, S. Aubrey Stoch, Margaret Fedgchin, Jack Valentine, Deborah Panebianco, Cynthia Gargano, Edward Pequignot
Publikováno v:
Cancer Chemotherapy and Pharmacology. 67:1313-1321
Because glucocorticoids and the neurokinin-1 receptor antagonist aprepitant influence CYP3A4 activity, this study assessed whether aprepitant added to a 5-HT3 antagonist and glucocorticoid would affect CYP3A4 induction. In this double-blind, 2-period
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3be1f6da7adb2feae4e9c6db5bbb8fa5
https://doi.org/10.1007/s00280-010-1421-y
https://doi.org/10.1007/s00280-010-1421-y
Autor:
James Dru, Diana V. Selverian, M.L Constanzer, Tuli Ahmed, Kevin J. Petty, Anup K. Majumdar, Howard E. Greenberg, Jacqueline B. McCrea, Kerri X. Yan, Glen S. Frick, Suna Barlas, Walter K. Kraft
Publikováno v:
The Journal of Clinical Pharmacology. 47:744-750
Oral aprepitant 125 mg, an antiemetic and a moderate inhibitor of the metabolism of oral midazolam, was assessed for interaction with intravenous midazolam in 12 subjects randomized to intravenous midazolam 2 mg +/- oral aprepitant 125 mg. The hypoth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24a439d4c297565d590aa34167dd5ed7
https://doi.org/10.1177/0091270007300807
https://doi.org/10.1177/0091270007300807
Autor:
Debbie Panebianco, Kristien Van Dyck, Kenneth R. Hande, Anup K. Majumdar, Keith Gottesdiener, Veronique Cocquyt, Simon Van Belle, Marina De Smet, Tuli Ahmed, Margaret Fedgchin, Peter Nygren, Kevin J. Petty, M. Gail Murphy
Publikováno v:
Cancer Chemotherapy and Pharmacology. 55:609-616
Aprepitant is a selective neurokinin-1 receptor antagonist that is effective for the prevention of nausea and vomiting caused by highly emetogenic chemotherapy. In vitro, aprepitant is a moderate inhibitor of the CYP3A4 enzyme, which is involved in t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85e1d8174dbca46a7cbc9464b6926691
https://doi.org/10.1007/s00280-004-0946-3
https://doi.org/10.1007/s00280-004-0946-3
Autor:
Thomas E. Bradstreet, Anup K. Majumdar, John Busillo, Kala-Jyoti Viswanathan Aiyer, Trisha Fosbinder, Thomas Marbury, Lisa Hickey, Arthur J. Bergman, Kevin J. Petty, Su-Er W. Huskey, Suzanne K. Swan, M.L. Constanzer
Publikováno v:
Clinical Pharmacokinetics. 44:637-647
Background: The neurokinin NK1-receptor antagonist aprepitant has demonstrated efficacy in preventing highly emetogenic chemotherapy-induced nausea and vomiting. Objective: The objective of the present study was to investigate the effects of impaired
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4db956950e19f1ffd8d9b584ec72f515
https://doi.org/10.2165/00003088-200544060-00005
https://doi.org/10.2165/00003088-200544060-00005
Autor:
Thomas E. Bradstreet, Craig R. Shadle, Robert A. Blum, Yih Lee, Judith K. Evans, Anup K. Majumdar, Cynthia Gargano, Kevin J. Petty
Publikováno v:
The Journal of Clinical Pharmacology. 44:215-223
The NK(1) receptor antagonist aprepitant (EMEND(R)), developed for use in combination with a 5HT(3) receptor antagonist and a corticosteroid to prevent highly emetogenic chemotherapy-induced nausea and vomiting (CINV), has been shown to have a modera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96a28f480a64219aa1832f901b72f72f
https://doi.org/10.1177/0091270003262950
https://doi.org/10.1177/0091270003262950
Autor:
Kevin J. Petty, Christopher R. Lines, Anup K. Majumdar, Deborah Panebianco, Keith Gottesdiener, Michael R. Goldberg, James Dru, Gail Murphy, Michael Hesney, Jacqueline B. McCrea, Robert A. Blum, M.L Constanzer
Publikováno v:
Clinical Pharmacology & Therapeutics. 74:150-156
Background Aprepitant is a neurokinin1 receptor antagonist that enhances prevention of chemotherapy-induced nausea and vomiting when added to conventional therapy with a corticosteroid and a 5-hydroxytryptamine3 (5-HT3) antagonist. Because aprepitant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0518dffd1b3bd42ea9e66431ab57e5bb
https://doi.org/10.1016/s0009-9236(03)00123-1
https://doi.org/10.1016/s0009-9236(03)00123-1
Autor:
D. Ronald Goldwater, Michael R. Goldberg, Kevin J. Petty, Michael Hesney, Christopher Lines, Marian Iwamoto, Anup K. Majumdar, Paul J. Deutsch, Deborah Panebianco, Cynthia Gargano, M. Gail Murphy, Jacqueline B. McCrea, Robert A. Blum, Keith Gottesdiener
Publikováno v:
Clinical Pharmacology & Therapeutics. 74:17-24
Background Aprepitant is a neurokinin1 receptor antagonist that, in combination with a corticosteroid and a 5-hydroxytryptamine3 receptor antagonist, has been shown to be very effective in the prevention of chemotherapy-induced nausea and vomiting. A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07bf8ef092d698298aec0d5f70b98ebf
https://doi.org/10.1016/s0009-9236(03)00066-3
https://doi.org/10.1016/s0009-9236(03)00066-3
Autor:
Susan X. Li, Howard E. Greenberg, Donald G. Musson, Peter J. Wickersham, S. Holland, Anup K. Majumdar, Alison L Fisher, G. Mistry, Kimberly L. Birk, Scott A. Waldman, Deutsch Paul J, J. Douglas Rogers
Publikováno v:
Antimicrobial Agents and Chemotherapy. 47:1732-1735
Ertapenem (INVANZ) is a new once-a-day parental β-lactam antimicrobial agent that has been shown to be highly effective as a single agent for treatment of various community-acquired and mixed infections. The plasma pharmacokinetics of a 1-g intramus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ec1dbf93ec6d3b1abfd847d20b786b7
https://doi.org/10.1128/aac.47.5.1732-1735.2003
https://doi.org/10.1128/aac.47.5.1732-1735.2003
Autor:
Michael Hesney, Walter K. Kraft, John Busillo, Kevin M. Gottesdiener, Christian D. Lates, Robert A. Blum, Howard E. Greenberg, Kevin J. Petty, M. Gail Murphy, Scott A. Waldman, Anup K. Majumdar, Sandi Van Buren, Michael R. Goldberg, Laura H. Orlowski, Carolyn M. Hustad, Jacqueline B. McCrea, Deborah Panebianco
Publikováno v:
Clinical Therapeutics. 25:1407-1419
Background: The neurokinin-1-receptor antagonist aprepitant, when given in combination with a corticosteroid and a 5-hydroxytryptamine type 3 (5-HT 3 )-receptor antagonist, has been shown to be effective for the prevention of acute and delated chemot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fa947d2b436ccb38857b9ee4c0ad30e
https://doi.org/10.1016/s0149-2918(03)80128-5
https://doi.org/10.1016/s0149-2918(03)80128-5